Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Biotest Biotech Co (SHSE:688767) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hangzhou Biotest Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥3,694.0 Mil.
Hangzhou Biotest Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Biotest Biotech Co EV-to-EBIT Related Terms
Hangzhou Biotest Biotech Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688767 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Hangzhou Biotest Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Biotest Biotech Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hangzhou Biotest Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hangzhou Biotest Biotech Co's EV-to-EBIT falls into.
Hangzhou Biotest Biotech Co's current Enterprise Value is ¥4,274.9 Mil.
Hangzhou Biotest Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Biotest Biotech Co (SHSE:688767) has a EV-to-EBIT of -46,976.89 as of Sep. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hangzhou Biotest Biotech Co and its competitors. According to the industry distribution chart, Hangzhou Biotest Biotech Co ranks #999999 out of 368 companies in the Biotechnology industry.
Is Hangzhou Biotest Biotech Co's EV-to-EBIT too high?
Hangzhou Biotest Biotech Co's current EV-to-EBIT is -46,976.89. Based on the distribution chart, Hangzhou Biotest Biotech Co ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Biotest Biotech Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Biotest Biotech Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hangzhou Biotest Biotech Co ranks #999999 out of 368 companies for EV-to-EBIT. This places Hangzhou Biotest Biotech Co in the lower half of its industry. The industry median EV-to-EBIT is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.50, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hangzhou Biotest Biotech Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Biotest Biotech Co's current EV-to-EBIT is -46,976.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Biotest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co (SHSE:688767) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥28.65, compared to a current price of ¥36.40 — trading 27.1% above its estimated fair value. The current EV-to-EBIT is -46,976.89. Hangzhou Biotest Biotech Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hangzhou Biotest Biotech Co (SHSE:688767), the current EV-to-EBIT is -46,976.89 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Biotest Biotech Co (SHSE:688767) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co stock appears to be overvalued.
The current stock price of ¥36.40 is trading 27.1% above its estimated GF Value™ of ¥28.65.
GuruFocus considers Hangzhou Biotest Biotech Co to be Modestly Overvalued.
Key valuation signals for SHSE:688767:
EV-to-EBIT: -46,976.89
GF Value™: ¥28.65 vs. price of ¥36.40 (27.1% above fair value)
No single metric tells the full story. See the SHSE:688767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Biotest Biotech Co Ltd is engaged in the research and development, manufacturing, sales and service of in vitro diagnostic reagents, raw materials and instruments.
71GF Score
Get the complete analysis for SHSE:688767
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688767 has been successfully added to your 
